Client Portfolio

Renowned Universities and Research Institutes

265 leading academic institutes are currently using genOway's services, among which:

(Please move your mouse over the map and click on the desired continent and country, a list appears under the map.)

  • World wide
  • North America
  • Europe
  • Asia
  • Oceania
 
 
 
 
 
 
 

 

 

USA - Kentucky

USA - Virginia

USA - Washington

France

Germany

United Kingdom

Major Biopharmaceutical Companies

genOway collaborates with more than 80 biopharmaceutical companies:

  • Actelion Pharmaceuticals Active Biotech AdvanceCor GmbG Alexion Pharmaceuticals Allergan  Alligator BioscienceAlnylam Pharmaceuticals Altana Pharma Arena Pharmaceuticals Ark Therapeutics Astellas Baxter Bayer BioAccelerate Biomérieux
  • Bio PharmBiotest Bio Tie Boehringer Ingelheim Bracco Bristol-Myers Squibb Company Cell Signaling Technologies  Chiesi Farmaceutici Chroma Therapeutics Daiichi Sankyo Daiinippon Sumitomo Pharma DBV Technologies Eisai Elan Laboratoires Pierre Fabre
  • Fate TherapeuticsGalderma Galenea Corporation Genentech Geneuro Genfit Genmab Glenmark Grunenthal  Immunogen ImmuNext Ingenium pharmaceuticals InterMune IPSEN Isis pharmaceuticals
  • JanssenJohnson & Johnson Kyowa Hakko Kirin Pharma Lilly Lundbeck Mellitech Merck KGaA Merck Serono Merck Sharp & Dohme VeoVacs Nestlé NeurOp NKT Therapeutics Inc Novartis Novo Nordisk A/S
  • NovozymesObe Therapy Biotechnology OMT Ono Pharmaceutical Orega Biotech Osi Prosidion Pfizer Preclin ProBioDrug Prothena Bioscience QPS Reata Pharmaceuticals Regulus Therapeutics Roche Laboratoires Servier
  • Shionogi & Co.Teva ThromboGenics UCB Pharma Venenum Xencor

EU 6th and 7th Framework projects

genOway is involved in EU 6th and 7th Framework for several projects as a SME partner:

  • Aggressotype: Aggression subtyping for improved insight and treatment innovation in psychiatric disorders
  • AtheroBCells: Targeting and exploiting B cell functions for treatment in cardiovascular diseases
  • AtheroRemo: Inflammation and Vascular Wall Remodeling in Atherosclerosis
  • EURO-DIA: Functional genomics of Pancreatic beta cells and of tissues involved in control of the endocrine pancreas for prevention and treatment of type 2 diabetes
  • EVI-GENORET: Functional Genomics of the Retina in Health and disease
  • MATRICS: Focuses on the subtyping of agression both within Disruptive Behaviour Disorders and of the broader cross-disorder trait of aggression
  • RiskyCAD: Developing novel diagnostic tools and treatments to enhance personalized medicine of high risk coronary artery disease (CAD) patients
  • TACTICS: Translational Adolescent and Childhood Therapeutic Interventions in Compulsive Syndromes
  • AD-Innov: Identify new therapeutics to treat Alzheimer disease (ended)
  • EPI-Vector: Treating genetic diseases by introducing functional genes into the human organism (ended)
  • EUGeneHeart: Genomics of Cardiomyocyte Signaling to Treat and Prevent Heart Failure (ended)
  • IT-Diab: Identify new targets implicated in the progression from prediabetes to Type 2 diabetes (ended)
  • MYORES: the European Muscle Development Network (ended)